Company Description
Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health.
Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders.
Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington’s disease, as well as various preclinical programs utilizing its RNA medicines platform.
Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2012 |
| IPO Date | Nov 11, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 317 |
| CEO | Paul B. Bolno |
Contact Details
Address: 733 Concord Avenue Cambridge, Massachusetts 02138 United States | |
| Phone | 617 949 2900 |
| Website | wavelifesciences.com |
Stock Details
| Ticker Symbol | WVE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001631574 |
| CUSIP Number | 94352A104 |
| ISIN Number | US94352A1043 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paul B. Bolno M.B.A., M.D. | President, Chief Executive Officer and Director |
| Dr. Gregory L. Verdine Ph.D. | Founder and Director |
| Kyle B. Moran CFA | Chief Financial Officer and Principal Accounting Officer |
| Dr. Chandra Vargeese Ph.D. | Chief Technology Officer |
| Dr. Erik Ingelsson M.D., Ph.D. | Chief Scientific Officer |
| Kate Rausch | Vic President of Corporate Affairs and Investor Relations |
| Linda Rockett J.D. | Senior Vice President and General Counsel |
| Katie Sullivan | Senior Director of Corporate Communications |
| Daryn Lewis | Senior Vice President and Head of Human Resources |
| Dr. Sridhar Vaddeboina M.B.A., Ph.D. | Senior Vice President of Chemistry, Manufacturing and Controls |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 27, 2026 | SCHEDULE 13G | Filing |
| Oct 27, 2026 | SCHEDULE 13G/A | Filing |
| Oct 27, 2026 | 10-Q | Quarterly Report |
| Oct 27, 2026 | 8-K | Current Report |
| Oct 14, 2026 | ARS | Filing |
| Oct 14, 2026 | DEF 14A | Other definitive proxy statements |
| Aug 14, 2026 | EFFECT | Notice of Effectiveness |
| Aug 12, 2026 | 144 | Filing |
| Aug 11, 2026 | SCHEDULE 13D/A | Filing |
| Aug 11, 2026 | 144 | Filing |